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ABSTRACT 32 
A decrease in the release rate over time is typically encountered when dealing with hydrophilic matrix systems 33 
for oral prolonged release due to progressive increase of the distance the drug molecules have to cover to 34 
diffuse outwards and reduction of the area of the glassy matrix at the swelling front. In order to solve this issue, 35 
a novel formulation approach based on non-uniform distribution of the active ingredient throughout the 36 
swellable polymer matrix was proposed and evaluated. Various physical mixtures of polymer (high-viscosity 37 
hypromellose) and drug tracer (acetaminophen), having decreasing concentrations of the latter, were applied 38 
by powder-layering onto inert core seeds. The resulting gradient matrices showed to possess satisfactory 39 
physico-technological characteristics, with spherical shape and consistent thickness of the layers sequentially 40 
applied. The non-uniform matrix composition pursued was confirmed by Raman mapping analysis. As 41 
compared with a system having uniform distribution of the drug tracer, the multi-layer formulations were 42 
proved to enhance linearity of release. The simple design concept, advantageous technique, which involves no 43 
solvents nor high-impact drying operations, and the polymeric material of established use make the delivery 44 
platform hereby proposed a valuable strategy to improve the performance of hydrophilic matrix systems. 45 
 46 
INTRODUCTION 47 
Tableted matrix systems for oral prolonged release of common cylindrical shape typically display a decrease 48 
in the rate of release over time due to progressive increase in the diffusional path the drug has to cover to reach 49 
the outer medium and concomitant reduction of the area at the solvent penetration front. Particularly in the 50 
case of hydrophilic matrices, an initial burst release may also be observed due to the fraction of drug present 51 
on the surface, which is released when the outer polymer particles are not fully swollen yet [1]. Because zero-52 
order kinetics has long been sought to attain constant drug absorption rate for a predetermined period of time, 53 
thus providing the patient with constant drug levels between two successive doses, several attempts to address 54 
these issues have been reported in the literature. The resulting systems are intended to reach the goal of a linear 55 
release pattern by the use of different strategies, which may involve mechanical restriction of swelling, 56 
application of partial coatings and/or design of modified geometries [2–10]. Overall, these approaches would 57 
be aimed at restraining the gradual extension of the diffusion path or progressively broadening the area at the 58 
solvent penetration front within the matrix. 59 
In addition, gradient systems, wherein the drug concentration increases from the outside towards the inside, 60 
have been described [11–18]. Such systems may be obtained by controlled extraction processes, 61 
coating/layering techniques or, alternatively, emerging fabrication methods, such as 3D printing and 62 
electrostatic deposition, that are still poorly exploited in the pharmaceutical field [19–23]. Coating is mainly 63 
based on liquid vehicles that not only require time- and energy-consuming drying phases, but also may bring 64 
about stability issues. In this respect, aqueous spray-coating would especially be critical when using 65 
hydrophilic polymers tending to generate too high viscosities and involving the use of diluted solutions [24,25]. 66 
Notably, powder-layering, wherein coating materials are directly layered as solids onto inert starting cores, 67 
may overcome most technical issues connected with liquid-based processes [26,27]. For these reasons, it was 68 
deemed to be an alternative technique that could advantageously be exploited for manufacturing of hydrophilic 69 
gradient matrices. 70 
Accordingly, the aim of the present study was to i) design a hydrophilic matrix system with non-uniform drug 71 
distribution (Non-Uniform Drug Distribution Matrix, NUDDMat) for prolonged release, intended to ultimately 72 
provide zero-order kinetics, ii) study the feasibility of powder-layering in the relevant manufacturing through 73 
application of successive layers having decreasing drug concentrations, and iii) evaluate the in vitro 74 
performance of the resulting prototypes. 75 
 76 
MATERIALS AND METHODS 77 
MATERIALS 78 
Acetaminophen fine powder British Pharmacopoeia (AAP, CFM, Italy) (water solubility 14.8 mg/mL, true 79 
density 1.13 g/mL [28–30]) was used as the tracer and high viscosity hypromellose (HPMC, Methocel® K15M, 80 
Colorcon, Italy) (apparent viscosity, 2% in water at 20 °C 6138–9030 mPa*s, USP substitution type 2208, true 81 
density 1.32 g/mL [31–33]) was selected as the hydrophilic swellable polymer. Lactose (Carlo Erba, Italy, true 82 
density 1.50 g/mL [34]) and dibasic calcium phosphate dihydrate (DCP, Emcompress®, JRS, Germany, true 83 
density 2.21 g/mL [35]) were evaluated as soluble and insoluble diluents. Fumed silica (Aerosil® 200, Evonik, 84 
Germany) was added as a glidant to the powder mixtures, and povidone (PVP, Kollidon® 30, BASF, Germany, 85 
true density 1.11 g/mL [36]) was used as the binder in aqueous solution. 86 
Nonpareil microcrystalline cellulose (MCC) pellets having nominal diameter of 850 µm were chosen as the 87 
starting cores (Cellets® 700, Pharmatrans-Sanaq, Switzerland, true density 1.46 g/L [37]). 88 
 89 
METHODS 90 
Manufacturing of tableted and layered units 91 
According to formulas set up during the experimental work, reported in the Results and Discussion section, 92 
powder blends to be tableted or layered were obtained by mixing in Turbula® (Willy A. Bachofen, Switzerland) 93 
at 24 rpm for 20 min. 94 
Tableting was performed by a rotary tablet press (mod. AM8S, Officine Meccaniche Ronchi, Italy) equipped 95 
with 4 mm diameter concave punches (4 mm curvature radius) at 7 kN compression force (batch size 50 g). 96 
The nominal weight of matrices was 45 mg. 97 
Powder layering was performed by a fluid bed (GPGC 1.1, Glatt, Germany) equipped with rotor insert. The 98 
operating conditions set up were as follows: nozzle port size 1.2 mm, air temperature in 30 °C, product 99 
temperature 26-28 °C, air temperature out 23 °C, air flow 70 m3/h, nebulization air pressure 2 bar, product 100 
pressure 1100 Pa, disk rotation speed 700 rpm, liquid binder feeding rate 12 g/min, powder feeder rate 20 101 
g/min. For any layering step, 500 g of starting substrate was loaded into the processing chamber. Powder 102 
addition was accomplished via forced powder feeder while spraying a binding solution onto preheated 103 
substrate cores. The diameter and weight of the coated units were regularly checked in-process by withdrawing 104 
samples (n=100) at prefixed time intervals. After each layering step, a post-processing drying phase was 105 
performed at inlet air temperature of 60 °C for 30 min. Process yield was calculated as the percentage weight 106 
ratio between the layered units and the employed materials (seeds, layering powders, binder). 107 
 108 
Physico-technological characterization of tableted and layered units 109 
Tableted (n=20) and layered (n=100) units were checked for weight and for thickness and/or diameter by a 110 
precision calliper (CD 150, Mitutoyo, Italy). 111 
The aspect ratio was calculated dividing the maximum by the minimum diameter of each unit, as measured by 112 
digital microscope (Dino Lite Pro AM 413T, Italeco, Italy) (n=20).  113 
Friability was assessed according to Eur. Ph. 9.2 by a friabilometer (mod. EF-2, Electrolab, Italy) rotating at 114 
25 rpm for 4 min. 6.5 g of units was used for the measurements. The data obtained were expressed as loss-on-115 
weight percentages. 116 
Crushing strenght (n=10) was measured by the equipment reported in Eur. Ph. 9.2 (mod. T3, Erweka, 117 
Germany). 118 
Porosity (E) of units, expressed as percentage, was calculated according to the equation: 119 
 120 
𝐸 (%) = [1 −
𝑉𝑡
𝑉𝑏
] ∙ 100 (1) 121 
 122 
where Vt is the true volume and Vb is the mean bulk volume. 123 
Cross-section morphology was analyzed by a scanning electron microscope (SEM; Sigma, Carl Zeiss, 124 
Germany). Samples were gold-sputtered using a plasma evaporator under vacuum, and photomicrographs were 125 
acquired at an accelerated voltage of 10 kV at differing magnifications. 126 
 127 
 128 
Release testing of tableted and layered units and data analysis 129 
Samples corresponding to an overall amount of 50 mg of AAP were tested for release by a Eur. Ph. 9.2 130 
dissolution apparatus (mod. 2100B, Distek Italia, Italy) equipped with rotating baskets using 900 mL of 131 
purified water at 37 ± 0.5 °C stirred at 100 rpm (n=3). AAP was assayed by spectrophotometer at 243 nm 132 
(Lambda 25, Perkin Elmer Italia, Italy) after verifying agreement of results with a HPLC method according to 133 
USP 40-NF 35 [38]. Samples of medium were collected at 4 selected time points (0.5–70.0 μg/mL 134 
concentration range) during the release test. Each sample was analyzed (n = 6) by both HPLC (column: C18 at 135 
40 °C, mobile phase: deionized water for HPLC/acetonitrile/perchloric acid 3000:1000:3, V/V/V, at pH 2.4, 136 
flow rate: 1.2 mL/min, detection: UV at 248 nm, injection volume: 40 μL) and UV using freshly prepared 137 
standard solutions as a reference. The 95% confidence intervals for the differences in the measured 138 
concentration means (UV minus HPLC) fell in the ±2% range with respect to the HPLC mean, in compliance 139 
with typical acceptance criteria [39]. For statistical comparison of release profiles, similarity factor f2 was 140 
applied. f2 ≥ 50 (50-100) indicated similarity [40].  141 
Release data from UDDMat systems were analyzed according to the equation: 142 
 143 
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛  (2) 144 
where Mt/M∞ is the drug fraction released at time t, n exponent indicates the mechanism/kinetics of release and 145 
k is a constant incorporating structural and geometrical characteristics of the matrix. Analysis of data was 146 
performed in the portion of the curve where Mt/M∞ <0.60, and confidence intervals (c.i.) at 95% were 147 
calculated [41–43]. 148 
Equation (2) was also used to fit release data from NUDDMat systems. In this case, the portion of the curve 149 
wherein Mt/M∞<0.90 was analyzed, and n values were used for descriptive purposes only to highlight 150 
progressive shift toward linearity. When n was = 1, the units were considered, from a merely phenomenological 151 
point of view, to behave as a zero-order release system, and values ˂ 0.5 and >1 could also be taken into 152 
account. 153 
The extent of linearity of release profiles was evaluated through the Durbin-Watson statistics, which enables 154 
to identify zero-order portions in each curve [42,44,45]. The release data were analyzed at time intervals of 1 155 
h, between 0.05 and 0.90 fractions released (90% c.i.). 156 
 157 
Raman mapping analysis 158 
Raman mapping analysis was performed on cross-sectioned units using a confocal microscope XploRA PlusTM 159 
(HORIBA Italia, Italy), under the following conditions: acquisition time 0.6 s, laser 785 nm, grating 600 160 
grooves/mm, objective 100x, spatial step size 40 μm, measured area 100×100 points (pixels) covering an area 161 
of 4000×4000 μm [46]. After acquiring Raman spectra of AAP, HPMC and DCP, the relevant identification 162 
was accomplished by a correlation algorithm through KnowItAll™ spectral database (HORIBA Italia, Italy). 163 
Hyperspectral mapping of the cross-sectioned systems was carried out moving the laser across the surface and 164 
acquiring a spectrum for each point. False color maps were generated after calibration of peaks related to the 165 
3 components considered: green was assigned to AAP, blue to HPMC (or cellulose) and red to DCP. Maps 166 
were created by applying fast mapping mode on SWIFT™ accessory to reduce acquisition time while 167 
maintaining high resolution of spectra. The intensity ratio between the colors assigned to AAP and HPMC 168 
(AAP/HPMC ratio) was calculated. The AAP/HPMC ratio was associated to a false color (turquoise), and 2D 169 
as well as 3D intensity maps were generated. Profiles of AAP/HPMC ratio versus diameter of the units were 170 
also constructed. 171 
 172 
RESULTS AND DISCUSSION  173 
 174 
Uniform Drug Distribution Matrix Systems 175 
With the aim of overcoming typical issues involved by hydrophilic matrices, namely the initial burst release 176 
and gradual decrease in the release rate, an alternative strategy was explored for the relevant formulation and 177 
manufacturing. Various swellable polymers have been proposed in the literature as matrix-forming agents, 178 
such as hypromellose (HPMC), hydroxypropylcellulose (HPC) and polyethylene oxide (PEO) [1]. HPMC is 179 
especially popular for the long-established regulatory acceptability and availability of different grades (degree 180 
of substitution, molecular weight, particle size). Methocel® K15M, a high viscosity HPMC, was selected for 181 
this study, and AAP was employed as an analytical tracer. Using a polymer percentage that could be considered 182 
sufficient for formation of a non-disintegrating swellable hydrophilic matrix, systems based on a 30:70 183 
HPMC/AAP mixture were first investigated (Table 1). Such systems were manufactured by either 184 
conventional tableting (UDDMat T30) or powder layering (UDDMat P30) in order to assess the application 185 
potential of the latter technique. For a successful outcome, powder layering requires the use of powders having 186 
adequate flowing and adhesion properties. While the flowability of this blend proved to be suitable not only 187 
for tableting but also for powder layering, the particle adhesion needed to be promoted by spraying a binder 188 
solution for effective deposition. PVP, HPC and HPMC have been reported to be the most commonly used 189 
binding agents for powder layering [47,48]. In particular, a 5% PVP (Kollidon® 30) solution was used, which 190 
displayed satisfactory binding properties and suitable viscosity for nebulization. 191 
  192 
 193 
Table 1: tracer/polymer/diluent percentage composition of the different powder blends to be tableted or layered° 194 
 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
 204 
° 0.75% of fumed silica was added to each powder formulation 205 
# composition of 1st-4th layers is the same as in NUDDMat G20-80 206 
* nominal thickness 157 um 207 
 208 
The powder layering process was performed by rotary fluid bed starting from 850 µm MCC seeds. Preliminary 209 
trials allowed the operating parameters to be adjusted. An efficient process was finally set up and a yield of 210 
88.7% was reached. Powder layering was continued until the diameter of the units was approximately of 4 mm 211 
as in the reference tableted matrices. The volume occupied by the starting seed was considered negligible. 212 
Systems having an average weight of 45.75 mg ± 0.74 s.d. and friability of 0.3% were obtained, which turned 213 
out comparable with tablets (weight 47.11 mg ± 0.29 s.d., friability 0.2%). Crushing strenght of layered 214 
UDDMat units was significantly higher than that of tablets, i.e. 55 N ± 8 s.d. versus 24 N ± 5 s.d. (p<0.01), 215 
respectively, probably owing to the use of an aqueous binder solution for layering. Interestingly, the two 216 
different techniques led to very similar porosity for tablets and layered units: 4.8% and 4.9%, respectively. 217 
Porosity, however, is known to only poorly influence the performance of hydrophilic matrices [49]. 218 
 219 
  220 
System code Layer AAP (%) HPMC (%) Lactose (%) DCP (%) 
UDDMat 
(Uniform Drug 
Distribution Matrices) 
T30 - 70 30 - - 
P30 - 70 30 - - 
NUDDMat 
(Non-uniform Drug 
Distribution Matrices) 
 
G20-80 
1st 80 20 - - 
2nd 65 35 - - 
3rd 50 50 - - 
4th 35 65 - - 
5th 20 80 - - 
G20-100 # 5th - 100 - - 
G20-100/2 #* 5th - 100   
G30-30L 
1st 65 30 5 - 
2nd 50 30 20 - 
3rd 35 30 35 - 
4th 20 30 50 - 
5th - 30 70 - 
G30-30D 
1st 65 30 - 5 
2nd 50 30 - 20 
3rd 35 30 - 35 
4th 20 30 - 50 
5th - 30 - 70 
The basket dissolution apparatus was employed for release tests since the layered systems exhibited a certain 221 
tendency to buoyancy. The use of sinkers with paddles was discarded because of major drawbacks in terms of 222 
swelling constraints. The systems having uniform drug distribution, irrespective of whether they had been 223 
manufactured by tableting or powder layering, showed a progressive decrease in the release rate over time 224 
after a slight burst release phase (Figure 1). Indeed, when using equation (2), n of 0.832 (0.061 c.i.) and 0.775 225 
(0.056 c.i.) obtained from tableted and layered matrices, respectively, highlighted non-fickian anomalous 226 
release behaviour. The difference observed in n values between almost cylindrical compressed and spherical 227 
layered matrices could be ascribed to the diverse shape, being included in the range predicted for cylinders 228 
and spheres [50]. An almost superimposable release pattern was seen (f2 = 68.75), indicating that neither the 229 
use of powder layering for this particular application, nor the composition change required, i.e. the addition of 230 
PVP in the binding solution, would significantly affect the release performance. 231 
 232 
 233 
Figure 1: release profiles from tableted (UDDMat T30) and layered (UDDMat P30) matrices with uniform drug 234 
distribution. Vertical bars represent standard deviations. 235 
 236 
Non-Uniform Drug Distribution Matrix Systems 237 
Powder layering was thus undertaken for the manufacturing of the Non-Uniform Drug Distribution Matrix 238 
(NUDDMat). This system was designed to include 5 overlaid layers differing in drug concentration, which 239 
decreased between contiguous layers from the inside towards the outside of the matrix according to a 240 
descending staircase function, ultimately tending to an apparent overall linear mode [13,17]. In Figure 2, a 241 
general outline of the NUDDMat system and layer-by-layer representation of the relevant theoretical drug 242 
concentration profile are presented. The nominal thickness of each layer was 315 µm aiming at a final diameter 243 
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of 4 mm, as in the previous systems having uniform drug distribution, including the diameter of the core (mean 244 
diameter 850 µm). 245 
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 252 
 253 
 254 
Figure 2: a) NUDDMat design concept (drug tracer concentration is indicated by color intensity); b) theoretical 255 
tracer concentration pattern along the radius (the dotted line indicates the overall decreasing trend of 256 
concentration).  257 
G20-80 was the first NUDDMat system prepared, according to the above-illustrated design concept. The 258 
nominal percentage composition of each layer was set based on prefixed AAP/HPMC ratios reported in Table 259 
1, taking the need for binder and glidant into account. PVP and fumed silica were maintained at 3.00% and at 260 
0.72%, respectively. 261 
In particular, the percentage of PVP was calculated based on a 5:3 weight ratio between layered powder and 262 
5% w/w binding solution. The amount of materials required for each layer was calculated based on the true 263 
density of the formulation components by assuming a layer porosity of 5% (Table 2). 264 
 265 
 266 
Table 2: nominal diameter, volume, weight, drug content and drug concentration, cumulative and for each layer, in 267 
NUDDMat G20-80 system 268 
Unit 
Cumulative 
diameter 
(mm) 
Layer 
volume 
(mm3) 
Cumulative 
volume  
(mm3) 
Layer 
weight 
(mg) 
Cumulative 
weight 
(mg) 
Layer 
drug content 
(mg) 
Cumulative 
drug content 
(mg) 
Layer  drug  
concentration  
(mg/mm3) 
Core seed 0.85 - 0.32 - 0.50 - - - 
1-layer 1.48 1.38 1.70 1.50 2.00 1.16 1.16 0.84 
2-layer 2.11 3.22 4.92 3.55 5.55 2.22 3.38 0.69 
3-layer 2.74 5.85 10.77 6.50 12.05 3.13 6.51 0.53 
4-layer 3.37 9.26 20.03 10.39 22.43 3.50 10.01 0.38 
5-layer 4.00 13.46 33.49 15.22 37.66 2.93 12.94 0.22 
 269 
It ensues that the theoretical total amount of drug tracer for each unit was approximately 13 mg, corresponding 270 
to 34.4% of the overall mass, the weight percentage of the starting seed being about 1.3%. 271 
Due to their differing compositions, the powder mixtures employed for the manufacturing of NUDDMat G20-272 
80 exhibited diverse flow properties ranging from very poor to poor according to Eur. Ph. 9.2 classification 273 
(compressibility index from 32% of the inner layer formulation to 28% of the outer one). Nevertheless, the 274 
powder feeding device in use allowed all mixtures to be loaded into the processing chamber of the fluid bed 275 
at a sufficiently reproducible rate consistent with continuous mode of dosing, and no formulation changes were 276 
needed. Powder adhesion onto the cores was expectedly enhanced with increasing percentage amounts of 277 
polymer in the mixtures. However, a 5% PVP solution, which was sprayed when layering the 30:70 278 
HPMC:AAP mixture within the preparation of UDDMat P30, proved also effective with the most critical 20:80 279 
blend, i.e. the formulation of the innermost layer. On the other hand, although simple spraying of water would 280 
have been possible with the mixtures having higher HPMC content, the same type and amount of binder 281 
solution was utilized for consistency in all powder layering steps. During the whole process, a 5:3 weight ratio 282 
was maintained between powder dosing rate (20 g/min) and binder spraying rate (12 g/min), so that the 283 
percentage of PVP could be the same in all layers. 284 
The powder layering process was run in 5 successive steps, each corresponding to a single layer, starting from 285 
a 500 g load of either inert seeds or intermediate layered units. By assuming a yield of 90%, the amount of 286 
powder formulation to be applied for each layer was calculated so that the desired 315 µm increase in thickness 287 
could be reached. When the whole quantity of powder blend needed per layer was loaded, the resulting layered 288 
units underwent a drying phase and were then checked for weight, diameter, porosity, crushing strenght, 289 
friability and aspect ratio (Table 3). The increases in weight and diameter were close to the expected values, 290 
although slightly higher data were generally obtained because of the process yield being greater then assumed. 291 
Porosity values turned out slighly higher than predicted with respect to those exhibited by UDDMat systems. 292 
The overall mechanical characteristics were proved satisfactory. Indeed, friability was approximately 0.4%, 293 
and crushing strenght was remarkably higher than in the case of both tableted and layered UDDMat systems 294 
having 30% of HPMC. The aspect ratio was around 1 thus indicating that NUDDMat G20-80 system had 295 
spherical shape, as confirmed by visual inspection (Figure 3).  296 
 297 
 298 
Figure 3: units ranging from the core seed to the final NUDDMat G20-80 system (scale in millimeters). 299 
 300 
The expected internal onion-like structure of NUDDMat G20-80, generated by discontinuous processing 301 
through application of powders with differing compositions, can barely be distinguished from SEM 302 
photomicrographs of a cross-sectioned unit (Figure 4). The dimple that is visible in the center of the system 303 
was left by the core seed, which was removed upon sectioning. 304 
 305 
 306 
Figure 4: SEM photomicrograph of a cross-sectioned NUDDMat G20-80 unit. 307 
 308 
The release profiles of the final NUDDMat G20-80 system and of the relevant intermediate units having 1 to 309 
4 layers are reported in Figure 5. 310 
 311 
 312 
Figure 5: release profiles from systems NUDDMat G20-80 and relevant intermediate units, NUDDMat G20-100 and 313 
NUDDMat G20-100/2. 314 
The n values resulting from data processing by exponential equation (2), here used for merely descriptive 315 
purposes, progressively increased thus pointing out a shift of the curves towards linearity (Table 4). 316 
One-layer units released the drug tracer rapidly due to a limited percentage amount of polymer. Indeed, the 317 
matrix structure could not withstand rapid erosion/disintegration, and the n value provided no meaningful 318 
information. On the other hand, with units having 2 or more layers, the formation of a swollen gel barrier was 319 
soon evident during the test. The rate of release decreased as a function of the number of layers. n values 320 
showed an increasing trend, thus indicating a shift towards linearity. Accordingly, the linear portion of the 321 
release curve from NUDDMat G20-80 (5 layers) ranged from 0.15 to 0.44 of fraction released, and the relevant 322 
time frame was 1÷4 h, as assessed by Durbin-Watson statistics. However, an initial phase of higher release 323 
rate could still be noticed. 324 
Aiming to overcome occurrence of this slight burst, a modified five-layer system, NUDDMat G20-100, was 325 
prepared and evaluated. In particular, the 5th layer of NUDDMat G20-100 was devoid of drug tracer, which 326 
was replaced by a corresponding amount of HPMC (Table 1). The physical technological characteristics were 327 
still satisfactory, and the outermost layer composed of sole polymer turned out effective in suppressing the 328 
undesired burst effect (Table 3, Figure 5). However, it brought about a lag time before the onset of release, as 329 
testified by n rising up to 1.121 (Table 4). Therefore, the thickness of the outer layer was halved in an attempt 330 
to reduce the lag time (NUDDMat G20-100/2), with no impact on mechanical properties was observed (Table 331 
3). This system proved useful to solve the lag phase issue and able to yield practically linear release curves 332 
(n=0.993) by preventing any burst effect (Figure 5, Table 4). Based on Durbin-Watson statistics, the profile 333 
turned out linear from 0.12 to 0.79 of fraction released, between 1 to 7 h. 334 
Interestingly, the onion-like structure of NUDDMat systems, which was expected to present concentration 335 
steps according to the descending staircase function conceived, was apparently not reflected in the release 336 
patterns obtained. Indeed, such steps might have been smoothed through partial migration of the drug tracer 337 
upon exposure to the aqueous binding solution during preparation and/or inward diffusion of the aqueous 338 
medium during release tests. 339 
Because the concentration of HPMC in the NUDDMat systems described so far, of approximately 60%, largely 340 
exceeded that usually employed for prolonged-release matrices, the possibility of reducing the overall amount 341 
of polymer was explored. Accordingly, systems with polymer content of 30% in all 5 layers, each of 315 µm, 342 
were conceived, wherein i) the amount of HPMC was increased in the first layer to the detriment of the drug 343 
tracer, ii) the amount of HPMC was decreased in the other 4 layers through replacement with an insoluble 344 
(DCP) and a soluble (lactose) excipient, and iii) no drug was loaded into the outer layer. The resulting 345 
formulations were named NUDDMat G30-30D and G30-30L, respectively, and the relevant compositions are 346 
reported in Table 1. In both cases, slightly improved powder layering processing was noticed, possibly due to 347 
the better flowability properties of the diluents as compared with HPMC. The lower amount of polymer was 348 
reflected in reduced crushing strenghts, which, however, still remained satisfactory (Table 3).  349 
As in previously described NUDDMat systems, the release rate decreased as the number of applied layers 350 
increased from all units, either containing DCP or lactose (data not shown). Approximately 80% of drug tracer 351 
was released in 7 h from both NUDDMat G30-30L and G30-30D, in an almost linear mode from the latter 352 
system (Figure 6). 353 
 354 
 355 
Figure 6: release profiles from NUDDMat G30-30L and NUDDMat G30-30D systems. 356 
A slight burst was observed in the relevant curve, even though no drug was contained in the outer layer. This 357 
could be attributed to destructuring of the swollen outer polymer layer caused by the dispersed particles of 358 
insoluble DCP, here present at the highest concentation of 70%. In contrast, release of the drug tracer from 359 
NUDDMat G30-30L was slowed down in the first hour of testing, probably because of soluble lactose bringing 360 
about fast formation of an external gel barrier responsible for initially slow diffusion. As shown before for 361 
G20-100, this issue could be counteracted by simply reducing the outer layer thickness. 362 
Interestingly, data from NUDDMat G30-30D and G30-30L indicated that partial replacement of the polymer 363 
would not impair the overall release control. 364 
 365 
  366 
Table 3: weight, size, porosity, aspect ratio, crushing strenght and friability of NUDDMat units 367 
 368 
 369 
Table 4: release parameters according to exponential equation (2) 370 
 n 
confidence 
interval 95% 
k R2 
UDDMat T30 0.832 0.061 0.229 0.989 
UDDMat P30 0.775 0.056 0.271 0.981 
1-layer unit * * * * 
2-layer unit 0.662 0.001 1.719 0.876 
3-layer unit 0.671 0.002 1.490 0.984 
4-layer unit 0.732 0.003 1.305 0.999 
NUDDMat G20-80 0.756 0.025 1.190 0.999 
NUDDMat G20-100 1.121 0.002 0.067 0.915 
NUDDMat G20-100/2 0.993 0.002 0.123 0.940 
NUDDMat G30-30L 1.227 0.003 0.809 0.986 
NUDDMat G30-30D 0.802 0.003 1.184 0.997 
*- Not applicable 371 
 372 
Raman mapping analysis  373 
In order to highlight the drug and polymer distribution throughout the layered formulations, it was deemed 374 
interesting to perform imaging analyses by Raman mapping microscopy. The distribution of the drug tracer 375 
particles within layered matrices was evaluated on cross-sectioned UDDMat P30 and NUDDMat G30-30D 376 
systems. The mapping was performed by assigning false colors to AAP, HPMC (or cellulose), DCP and to the 377 
AAP/HPMC ratio after identification of specific peaks of the spectra (Figure 7). Although no HPMC was 378 
contained in the seed formulation, quite a strong blue signal was highlighted, because cellulose, namely MCC, 379 
was present as the main component. 380 
  381 
NUDDMat unit  
Weight  
(mg ± s.d.) 
Diameter  
(mm ± s.d.) 
Porosity 
(%) 
Aspect ratio 
(value ± s.d.) 
Crushing strenght 
(N ± s.d.) 
Friability  
(%) 
G20-80 43.22±0.34 4.20 ±0.13 5.73 1.05 ± 0.04 204 ± 23 0.42 
G20-100 40.36 ±0.29 4.11 ±0.12 6.47 1.06 ± 0.03 165 ± 17 0.01 
G20-100/2 33.89 ±0.41 3.87 ±0.14  6.16 1.07 ± 0.04 170 ± 15 0.02 
G30-30L 49.43 ±0.68 4.26 ±0.21 5.59 1.02 ± 0.02 125 ± 10 0.33 
G30-30D 58.05 ±0.79 4.13 ±0.16 7.35 1.03 ± 0.02 146 ± 8 0.13 
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Figure 7: Raman mapping microscopy images relevant to AAP, HPMC, DCP and AAP/HPMC ratio acquired from 383 
cross-sectioned UDDMat P30 and NUDDMat G30-30D systems. Mapping refers to areas of approximately 4000 x 384 
4000 µm. 385 
 386 
The color intensity of AAP/HPMC ratio was plotted along the diameter of the cross-sectioned units (Figure 387 
8). 388 
  389 
 390 
a) 391 
 392 
b)  393 
 394 
Figure 8: profiles of AAP/HPMC ratio calculated from Raman mapping microscopy images along the diameter of 395 
cross-sectioned UDDMat P30 (a) and NUDDMat G30-30D (b) systems 396 
 397 
In the UDDMat P30 system, the AAP/HPMC intensity ratio profile, calculated along one diameter, suggested 398 
a uniform concentration of AAP throughout the layered powders and pointed out the sole presence of cellulose 399 
in the seed core (Figure 8 a). For NUDDMat G30-30D, a gradient of AAP/HPMC intensity ratio indicated a 400 
non-uniform concentration of drug tracer, decreasing from the inside to the outside of the unit. Particularly, a 401 
rise towards the center and a steep fall close to the core, devoid of drug, were highlighted, exactly matching 402 
the 3D hyperspectral map (Figure 8 b, Figure 9). The lack of a staircase concentration pattern, previously 403 
hypothesized from the evaluation of the release curves, seemed to be confirmed by the AAP/HPMC intensity 404 
ratio profile. 405 
 406 
 407 
 408 
Figure 9: hyperspectral 3D mapping by Raman microscopy relevant to color intensity of AAP/HPMC ratio acquired 409 
from a NUDDMat G30-30D system. Mapping refers to areas of approximately 4000 x 4000 µm. 410 
 411 
 412 
CONCLUSIONS 413 
A hydrophilic matrix system intended for zero-order release was designed and fabricated by subsequent 414 
deposition onto inert cores of layers having outwards decreasing drug concentrations. For this purpose, the use 415 
of powder layering was explored, which offers major advantages because of the small amount of solvents 416 
involved and reduced costs as compared with other layering techniques. Spherical units of 4 mm in diameter 417 
were thereby obtained, exhibiting satisfactory physico-technological characteristics. The non-uniform 418 
composition of the layered matrix, varying along its cross-sectional axis, was highlighted by Raman mapping 419 
analysis. The particular configuration of NUDDMat was demonstrated to reduce the initial burst effect typical 420 
of hydrophilic matrices, which, as expected, was yielded by a formulation having equal overall composition 421 
though uniform drug distribution. Moreover, this configuration proved effective in contrasting other 422 
drawbacks that are associated with hydrophilic matrices, such as the lengthening of the diffusional pathway 423 
and reduction of the area at the swelling front, both responsible for a progressive decrease in the release rate. 424 
The desired zero-order release profiles were thus obtained from the NUDDMat system, as confirmed through 425 
Durbin-Watson statistics that pointed out extension of the linear portion of release curves. 426 
As regards drug loading, the NUDDMat technology proposed would in principle not differ from classical 427 
hydrophilic matrix systems. Actually, based on the NUDDMat G20-100/2 formulation yielding zero-order 428 
release, which already contained around 33% of tracer, drug content higher than 50% could be achieved. The 429 
percentage of polymer could indeed be reduced in the innermost layers provided that in the outer one it is 430 
maintained at least in a 20-30% range, needed to ensure matrix structure formation upon glassy-rubbery 431 
transition. The simple design concept of the novel gradient composition matrix and the use of a more 432 
advantageous technique as compared with previous attempts reported in the literature make the delivery 433 
platform hereby proposed a valuable strategy to improve the performance of hydrophilic matrix systems for 434 
prolonged release. 435 
 436 
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